SBC Medical Reports Q1 Growth and Launches Share Buyback Program

SBC Medical Group Holdings Inc. reported strong first-quarter performance, highlighting strategic efforts to transform its business model and capitalize on the growing global aesthetic medical market. The company achieved notable financial improvements, with earnings per share increasing 5% year-over-year to $0.21 and EBITDA margins rising from 46% to 52%.

Despite a 14% revenue decline attributed to divesting certain business segments, the company expanded its clinic network to 251 locations, a 36-clinic increase from the previous year. Customer base growth of 14% to 6.1 million and a 71% repeat customer rate underscore the company's market appeal and service quality.

CEO Yoshiyuki Aikawa emphasized the company's strategic focus on expanding Medical Corporations (MCs), which help cosmetic practitioners navigate regulatory requirements while operating surgery centers. The company aims to make aesthetic medicine more accessible and differentiate itself through advanced treatments and competitive pricing.

In a significant move demonstrating confidence in its growth trajectory, SBC Medical announced a $5 million share buyback program running from May 20, 2025, to May 20, 2026. The company believes its current stock price undervalues its performance and potential, particularly in a global cosmetic surgery market projected to grow at a 14.7% compound annual growth rate through 2030.

The buyback strategy includes purchasing shares at market prices and potentially issuing shares for future stock-based compensation. Additionally, the company continues to explore dividend distributions to enhance shareholder returns.

With plans to expand into the U.S. and Singapore markets and a demonstrated ability to adapt to changing market dynamics, SBC Medical is positioning itself as a strategic player in the global aesthetic medical services sector.